These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11890357)

  • 1. Omapatrilat. Bristol-Myers Squibb.
    Tabrizchi R
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1414-22. PubMed ID: 11890357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omapatrilat for the management of heart failure and hypertension.
    Husereau DR
    Issues Emerg Health Technol; 2001 Jun; (17):1-4. PubMed ID: 11776285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Omapatrilat--new drug for patients with hypertension and heart failure].
    Dzielska-Olczak M
    Pol Merkur Lekarski; 2005 Oct; 19(112):556-8. PubMed ID: 16379325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omapatrilat--the story of Overture and Octave.
    Coats AJ
    Int J Cardiol; 2002 Nov; 86(1):1-4. PubMed ID: 12243845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent clinical trials with omapatrilat: new developments.
    Zanchi A; Maillard M; Burnier M
    Curr Hypertens Rep; 2003 Aug; 5(4):346-52. PubMed ID: 12844471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopeptidase inhibitors.
    Weber MA
    Lancet; 2001 Nov; 358(9292):1525-32. PubMed ID: 11705582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE).
    Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K
    Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasopeptidase inhibition: a new concept in blood pressure management.
    Burnett JC
    J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trial logistics, implementation, and conduct of the OCTAVE mega study in Germany. Prospective, randomised, double-blind study to compare the efficacy and tolerability of omapatrilat and enalapril.
    Kothny W; Kaaden R; Ludwig P; Chase D; Krekler M
    Arzneimittelforschung; 2004; 54(8):474-9. PubMed ID: 15460215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial.
    Rouleau JL; Pfeffer MA; Stewart DJ; Isaac D; Sestier F; Kerut EK; Porter CB; Proulx G; Qian C; Block AJ
    Lancet; 2000 Aug; 356(9230):615-20. PubMed ID: 10968433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined neutral endopeptidase inhibitors.
    Cuculi F; Erne P
    Expert Opin Investig Drugs; 2011 Apr; 20(4):457-63. PubMed ID: 21323474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept. Immunex.
    Pugsley MK
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1725-31. PubMed ID: 11892935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omapatrilat.
    Armstrong PW; Lorell BH; Nissen S; Borer J
    Circulation; 2002 Aug; 106(6):e9011-2. PubMed ID: 12187916
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vasopeptidase inhibitors. Omapatrilat in hypertension and heart failure].
    Heinzl S
    Med Monatsschr Pharm; 2000 Feb; 23(2):38-41. PubMed ID: 10701306
    [No Abstract]   [Full Text] [Related]  

  • 15. BMS-232632 (Novartis/Bristol-Myers Squibb).
    Witherell G
    Curr Opin Investig Drugs; 2001 Mar; 2(3):340-7. PubMed ID: 11575702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial.
    Kostis JB; Packer M; Black HR; Schmieder R; Henry D; Levy E
    Am J Hypertens; 2004 Feb; 17(2):103-11. PubMed ID: 14751650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris.
    Chaitman BR; Ivleva AY; Ujda M; Lenis JH; Toth C; Stieber DM; Reisin LH; Pangerl AM; Friedman JB; Lawrence JH
    Am J Cardiol; 2005 Jun; 95(11):1283-9. PubMed ID: 15904630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Valdecoxib (Pharmacia).
    Gotta AW
    Curr Opin Investig Drugs; 2002 Feb; 3(2):240-5. PubMed ID: 12020053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omapatrilat: a unique new agent for the treatment of cardiovascular disease.
    Nawarskas JJ; Anderson JR
    Heart Dis; 2000; 2(3):266-74. PubMed ID: 11728268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exubera. Inhale therapeutic systems.
    Bindra S; Cefalu WT
    Curr Opin Investig Drugs; 2002 May; 3(5):758-62. PubMed ID: 12090549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.